BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29788903)

  • 1. Sustained efficacy following resolution of frequent heartburn with an over-the-counter regimen of esomeprazole 20 mg or placebo for 14 days: two randomized trials.
    Peura DA; Le Moigne A; Wassel H; Pollack C
    BMC Gastroenterol; 2018 May; 18(1):69. PubMed ID: 29788903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 14-day regimen of esomeprazole 20 mg/day for frequent heartburn: durability of effects, symptomatic rebound, and treatment satisfaction.
    Peura D; Le Moigne A; Pollack C; Nagy P; Lind T
    Postgrad Med; 2016 Aug; 128(6):577-83. PubMed ID: 27331882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of 2-Week Data from Two Randomized, Controlled Trials Conducted in Subjects with Frequent Heartburn Treated with Esomeprazole 20 mg.
    Katz PO; Le Moigne A; Pollack C
    Clin Ther; 2017 May; 39(5):960-970. PubMed ID: 28431766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Esomeprazole treatment of frequent heartburn: two randomized, double-blind, placebo-controlled trials.
    Peura DA; Traxler B; Kocun C; Lind T
    Postgrad Med; 2014 Jul; 126(4):33-41. PubMed ID: 25141241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Clinical Predictors of Resolution of Sleep Disturbance Related to Frequent Nighttime Heartburn and Acid Regurgitation Symptoms in Individuals Taking Esomeprazole 20 mg or Placebo.
    Johnson DA; Le Moigne A; Li J; Pollack C; Nagy P
    Clin Drug Investig; 2016 Jul; 36(7):531-8. PubMed ID: 27074935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.
    Miner PB; Johnson DA; Katz PO; Li J; Gatoulis SC; Pollack C
    Adv Ther; 2018 Nov; 35(11):2024-2040. PubMed ID: 30255418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the symptom response to esomeprazole 20 mg over days 1-4 of a 14-day course of treatment for frequent heartburn: results of two randomised controlled trials.
    Peura D; Le Moigne A; Wassel H; Pollack C
    BMJ Open Gastroenterol; 2019; 6(1):e000278. PubMed ID: 31297231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in two randomized, double-blind, controlled trials.
    Johnson DA; Le Moigne A; Hugo V; Nagy P
    Curr Med Res Opin; 2015 Feb; 31(2):243-50. PubMed ID: 25478944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitors.
    Boardman HF; Heeley G
    Int J Clin Pharm; 2015 Oct; 37(5):709-16. PubMed ID: 26100836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial.
    Fass R; Sontag SJ; Traxler B; Sostek M
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):50-6. PubMed ID: 16431305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
    Labenz J; Armstrong D; Zetterstrand S; Eklund S; Leodolter A
    Aliment Pharmacol Ther; 2009 May; 29(9):959-66. PubMed ID: 19222417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of antireflux treatment on the frequency of awakenings from sleep in patients with Gastroesophageal reflux disease.
    Jha LK; Maradey-Romero C; Gadam R; Hershcovici T; Fass OZ; Quan SF; Guillen J; Fass R
    Neurogastroenterol Motil; 2015 Feb; 27(2):237-45. PubMed ID: 25484104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity does not affect treatment outcomes with proton pump inhibitors.
    Sharma P; Vakil N; Monyak JT; Silberg DG
    J Clin Gastroenterol; 2013 Sep; 47(8):672-7. PubMed ID: 23442835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis.
    Xue Y; Qin X; Zhou L; Lin S; Wang L; Hu H; Xia J
    Clin Drug Investig; 2016 Dec; 36(12):985-992. PubMed ID: 27605258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitor.
    Tack J; Vladimirov B; Horny I; Chong CF; Eisner J; Czerniak R; Takanami Y
    Neurogastroenterol Motil; 2023 Jan; 35(1):e14468. PubMed ID: 36178335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom-relieving effect of esomeprazole 40 mg daily in patients with heartburn.
    Johnsson F; Hatlebakk JG; Klintenberg AC; Román J
    Scand J Gastroenterol; 2003 Apr; 38(4):347-53. PubMed ID: 12739705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.
    Kushner PR; Snoddy AM; Gilderman L; Peura DA
    Postgrad Med; 2009 Jul; 121(4):67-75. PubMed ID: 19641272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis.
    Katz PO; Castell DO; Levine D
    Aliment Pharmacol Ther; 2003 Nov; 18(9):875-82. PubMed ID: 14616151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of regurgitation on health-related quality of life in gastro-oesophageal reflux disease before and after short-term potent acid suppression therapy.
    Kahrilas PJ; Jonsson A; Denison H; Wernersson B; Hughes N; Howden CW
    Gut; 2014 May; 63(5):720-6. PubMed ID: 23831734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.